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Abstract
MicroRNAs (miRNAs) are small non-coding RNAs that regulate gene expression and thus
influence many cellular and physiological processes. miRNAs are also present in cell-free
body fluids such as plasma or serum, and these circulating miRNAs are very stable, sensi-
tive, and specific biomarkers of pathophysiological states. In this study, we investigated
whether circulating miRNAs could serve as biomarkers of exogenous testosterone adminis-
tration. Misuse of testosterone as a performance-enhancing drug is thought to be wide-
spread in sports. Detection of testosterone through the urinary steroid profile of the Athlete
Biological Passport faces several obstacles, indicating that new biomarkers are required.
To this end, we analyzed plasma miRNA levels by high-throughput quantitative real-time
PCR. Plasma samples were obtained before and at several time points after transdermal
and oral testosterone administration. Screening identified three potential candidate miRNAs
that were altered by both routes of testosterone administration. Longitudinal monitoring of
these candidates revealed that variation in two of them (miR-150 and miR-342), relative to
the corresponding levels in control samples, was testosterone-independent. However, lev-
els of the liver-specific miR-122 increased 3.5-fold 1 day after drug intake. Given that testos-
terone is metabolized by the liver, this observation suggests that miR-122 in cell-free fluids
may be used as a sensitive biomarker of testosterone misuse via multiple dosing routes and
could therefore be integrated into a blood-based multiparametric follow-up.
Introduction
Testosterone, the principal endogenous androgenic anabolic steroid (EAAS), is secreted by
endocrine glands. It regulates many physiological processes in adult males, including muscle
protein metabolism, sexual and cognitive functions, erythropoiesis, hepatic lipid metabolism,
and bone metabolism [1, 2]. Although its use in sports is prohibited by the World Anti-Doping
Agency (WADA), testosterone is widely abused by athletes as a performance-enhancing drug
[3]. In addition to their anabolic action, small doses of anabolic-androgenic steroids can also
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lower fatigue levels, and accelerate recovery, leading to a higher training load and faster
increase in physical performance [4].
In doping control, screening for testosterone (T) misuse is primarily performed by GC-MS
and GC-MS/MS through assessment of a urinary steroid profile that includes T, its precursors,
and its metabolites. For several decades, evaluation of the ratio of testosterone to epitestoster-
one (T/E) has been the gold standard for screening for T administration. Based on population
references, a cut-off value of 4 was established as the threshold for this ratio [5]. When the ratio
exceeds the threshold, urine samples are submitted for confirmation analysis with GC-C-IRMS
[4]. However, despite its sensitivity and specificity, the T/E biomarker suffers from a short
detection window, particularly when T is taken orally, as well as high inter-individual variabil-
ity due to natural high T/E and genetic polymorphism [6–8]. To overcome these limitations
and improve the ability to detect T, the urinary steroidal module of the Athlete Biological Pass-
port (ABP) was recently implemented (January 1, 2014). This module relies on a longitudinal/
multiparametric approach using specific markers of altered metabolism of endogenous steroi-
dal hormones, including T/E and other metabolites ratios (Androsterone (A)/T, A/Etiochola-
nolone (Etio), 5α-Adiol/5β-Adiol), for each athlete using intra-individual references generated
by a Bayesian Adaptive Model [9].
However, more than 1 year after its implementation, the efficacy of the steroidal module of
the ABP is still in question, principally due to instability of urine samples (bacterial contamina-
tion, medications, enzyme induction-inhibition, etc.) and polymorphism of the UGT2B17
gene, which encodes a protein responsible for testosterone glucuronidation [10–12]. Therefore,
new approaches and potential biomarkers of T abuse must be investigated to improve the dis-
criminative performance of the ABP.
MicroRNAs (miRNAs), a class of small non-coding RNAs about 22 nucleotides in length
[13], regulate gene expression post-transcriptionally by decreasing mRNA stability or inhibit-
ing translation of mRNA into protein. Consequently, miRNAs are implicated in many cellular
processes such as differentiation, proliferation, metabolism, and apoptosis [14, 15]. Recently,
miRNAs were detected in various body fluids, including urine, plasma, serum, saliva, and tears
[16]. Although the physiological functions and regulation of these so-called ‘circulating miR-
NAs’ are largely unknown, they are associated with specific pathophysiological states such as
cancers and cardiovascular diseases [17–19]. In an anti-doping context, multiple groups
reported associations between altered plasma miRNA expression profiles and doping interven-
tions such as erythropoiesis-stimulating agents (ESA), autologous blood transfusion, and
recombinant growth hormone (rhGH) administration [20–23]. In comparison with proteins,
circulating miRNAs offer non negligible advantages as non-invasive biomarkers. miRNAs are
highly stable in body fluids, and are resistant to RNases, fluctuations in pH, and to multiple-
freeze/thaw cycles [24, 25]. In addition, expression of many miRNAs is specific to a tissue or
cell type [26], and their levels can be easily measured using common laboratory techniques,
including amplification-associated methods that require very small sample volumes [27].
Therefore, in this study we investigated whether circulating miRNAs can be used as surro-
gate biomarkers of testosterone abuse via various dosing routes. We compared the resultant
data with both commonly measured parameters and emerging parameters.
Material and Methods
Clinical study
All samples were derived from a previous clinical study that included 19 healthy male volun-
teers aged 19–28 (mean 24.3 ± 2.7 years) with BMI between 18.3 and 27.2 kg/m2 (mean
23.1 ± 2.4) and different UGT2B17 genotypes (ins/ins, ins/del, and del/del) [6]. All subjects
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gave signed consent form and the protocol was authorized by the Ethical Commission for the
Clinical Research of the Faculty of Biology and Medicine (University of Lausanne, Switzerland)
and Swissmedic (Protocol no. 155/11). The clinical trial took place over 5 weeks, divided into
four major phases (S1 Fig): the first week was dedicated to collection of control samples (no
treatment), followed by the administration of two transdermal systems that delivered 2.4 mg/
24 h (Testopatch1, Pierre Fabre Pharma GMBH, Freiburg, Germany) during the second week.
After a wash-out period of 2 weeks, two 40 mg testosterone undecanoate (TU) tablets (Andriol
Testocaps1, Essex Chemie AG, Luzern, Switzerland) were ingested by each volunteer. First
blood collection was performed at 07:00 AM. Plasma and serum samples were centrifuged at
1500 x g for 15 min after 15 min stabilization at room temperature. Plasma and serum aliquots
were kept at -20°C until analyses as described in [6].
miRNA quantitative real-time PCR (qRT-PCR)
Total RNA, including miRNAs, was isolated from 200 μl of plasma using the miRCURY RNA
Isolation Kit—Biofluids (Exiqon, Vedbaek, Denmark) with minor modifications. Briefly,
before RNA extraction, all plasma or serum samples were thawed completely, followed by cen-
trifugation at 16,000 × g for 10 min to remove remaining cell debris and platelets [28, 29]. Dur-
ing the treatment with lysis buffer, 1 μl of spike-in mix containing synthetic UniSp2, UniSp4,
and Unisp5 and 1 μl of cel-miR-39-3p (RNA Spike-in Kit, Exiqon) were added to the samples
as a control for extraction efficiency. After protein precipitation, supernatant was loaded onto
spin columns. Finally, the purified RNA was eluted with 35 μL RNAse free-water.
For miRNA profiling, 4 μL of eluted RNA was used in a 20-μL reverse transcription (RT)
reaction. UniSp6 Spike-in miRNA was added to the RT reaction mix. The resulting cDNA was
diluted 110 times and profiled for the relative abundance of 372 miRNAs using miRNA Ready-
to-Use PCR, Human panel I, V4.R quantitative real-time PCR (qRT-PCR) arrays (Exiqon), as
described in [21]. Raw data were analyzed using the LightCycler 480 software (version 1.5.0).
All primer sequences are available on the Exiqon web site (http://www.exiqon.com/mirna-pcr-
primer).
Hematology, clinical chemistry, and immunology
Blood parameters were analyzed in EDTA samples using a fully automated hematology ana-
lyzer (Sysmex XT-2100i, Sysmex, Norderstedt, Germany). Free T was measured in serum using
Immulite technology (Siemens AG, Munich, Germany). Alanine aminotransferase (ALT),
aspartate aminotransferase (AST), and C-reactive protein (CRP) serum levels were measured
using a Dimension EXL200 automated system (Siemens Healthcare Diagnostic SA, Zurich,
Switzerland).
Statistics
Unless specified otherwise, data are expressed as means ± SEM versus baseline. Statistical com-
parisons were performed using the two-tailed Student’s t-test (for free T) or non-parametric
Wilcoxon signed-rank test (for miRNA levels). Differentially expressed miRNAs were identi-
fied using the R package LIMMA as described in [21]. P< 0.05 was considered to represent a
statistically significant difference. Average Ct corresponds to the mean of Ct values at 0 and 24
h. Fold-Change (FC) was calculated from Ct values. Conditions were compared by one-way
ANOVA (the aov function in R) and post-hoc pairwise comparisons were performed with
Tukey’s Honestly Significant Difference (the TukeyHSD function in R). Descriptive and statis-
tical comparisons were performed using various softwares (Microsoft Office Excel 2007, Sta-
taIC, StataCorp and R).
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Results
To investigate the utility of circulating miRNAs as biomarkers of testosterone misuse, miRNA
profiling was performed by RT-PCR in samples obtained before (0 h) and at various time
points after (12 and 24 h) oral and transdermal T administration (S1 Table). Data were ana-
lyzed using a linear model that paired values by subjects. Out of 372 miRNAs tested, 134
(including controls) were detected after ingestion of two TU tablets, and 143 were detected
after application of diffusion patches. This screen enabled to identify the circulating miRNAs
that were most affected by T administered by different routes (Table 1 and S2 Table). These
candidates were selected for further investigations.
Significant variations in the levels of candidate miRNAs were only observed 24 h after tes-
tosterone intake via either route. Most circulating miRNAs decreased>2-fold at 24 h versus 0
h after administration; of these, miR-342 and miR-150 were the only miRNAs that were signifi-
cantly affected by oral and transdermal T administration. By contrast, miR-122 was the only
miRNA whose abundance increased under both conditions (2.3-fold on average). These miR-
NAs were selected for further analyses because of their abundance, statistical significance and
fold change.
Profiling of circulating miRNAs as biomarkers of T also permitted to identify miRNAs that
were not responsive to the treatment (S3 Table). Among these, miR-486-5p exhibited a low
coefficient of variation across all samples under both conditions and was present at high levels
in plasma. Therefore, miR-486-5p was selected as an internal control for RT-PCR validation.
The results of the screen were confirmed by individual assays throughout the timeline, with
special emphasis on the three miRNAs identified as candidate markers of T administration.
Measurements of miR-342 and miR-150 at the various time points confirmed the screening
results: the levels of both miRNAs decreased significantly 24 h after T administration relative
to their levels at 0 h (prior to T administration) (Fig 1). For miR-342, the decrease was also sig-
nificant 2 and 8 h after transdermal T application (Fig 1A). However, when observing the
kinetics of these two miRNAs during the control period, we noticed that the curves resembled
those of the T periods. The three conditions differed primarily in regard to the baseline levels
of miR-342 and miR-150.
T administration induced miR-122 with a peak occurring 24 h after drug intake (Fig 2).
Consistent with the screening results, the increase in plasma miR-122 level was evident only at
24 h after T administration. Exogenous testosterone increased the levels of this circulating
miRNA by an average of 4-fold. The amplitude of variation between baseline and 24 h was
larger after ingestion of TU than after application of diffusion patches (Fig 2). During the con-
trol phase, the plasma level of miR-122 did not change significantly.
Circulating miR-122 level was integrated in an individual longitudinal follow-up setting
subject-based threshold (Fig 3). For each subject, the threshold was calculated as the mean +
three standard deviations (SD) of the values during the control phase [6, 7, 30]. Fig 3 shows
measurements of miR-122 levels over time in two volunteers with different UGT2B17 geno-
types following oral T administration, along with their individual thresholds.
Because miR-122 is highly expressed by the liver, the activity of hepatocellular enzymes
(ALT/AST) was also determined in the serum of volunteers. In these analyses, the focus was
placed on samples that exhibited a large increase of plasma miR-122 following T administra-
tion. However, longitudinal monitoring revealed no significant changes in either enzyme over
time (S2 Fig). Likewise, no significant change was observed in CRP, a biochemical marker of
leukocytes, after T administration (S2 Fig).
Because intake of exogenous T is thought to affect endogenous T concentration, serum free
T concentrations of volunteers were measured by immunoassay under each condition (Fig 4).
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Table 1. miRNAsmost affected by testosterone. List of the 12 most affected miRNAs 1 day after ingestion of two TU tablets or application of two Testo-
patches, identified by miRNA expression profiling.




















2.2 -1.07 5.17 30.24 0.015168 hsa-miR-
122-5p
2.3 1.34 3.95 30.45 0.000812
hsa-miR-
146b-5p
-2.1 -3.66 -1.21 35.08 0.002894 hsa-miR-
425-5p
-1.65 -2.63 -1.04 30.52 0.006124
hsa-miR-
629-5p
-2.39 -4.04 -1.41 34.15 0.002396 hsa-miR-
324-3p
-1.76 -2.48 -1.25 32.74 0.002622
hsa-miR-
29b-3p
-2.51 -4.5 -1.4 33.91 0.001766 hsa-miR-
582-5p
-1.97 -3.76 -1.04 34.76 0.005832
hsa-miR-29c-
3p
-2.64 -5.76 -1.21 32.1 0.003952 hsa-let-7c-5p -2 -3.92 -1.02 34.68 0.007064
hsa-miR-
874-3p
-2.93 -6.3 -1.36 33.99 0.002421 hsa-let-7g-
5p
-2.1 -4.56 1.03 28.93 0.009684
hsa-miR-
361-5p
-2.99 -5.58 -1.6 31.47 0.002397 hsa-miR-
423-5p
-2.13 -3.57 -1.27 31.59 0.001973
hsa-miR-
140-3p
-3.16 -9.05 -1.11 28.91 0.006288 hsa-miR-
29a-3p
-2.95 -9.75 1.12 30.99 0.009417
hsa-miR-
423-3p
-3.21 -8.84 -1.17 31.83 0.010688 hsa-miR-
342-3p
-2.99 -9.08 1.02 28.86 0.005837
hsa-miR-
29a-3p
-3.59 -8.82 -1.46 31.36 0.000905 hsa-miR-
338-3p
-3.07 -7.59 -1.24 33.78 0.001644
hsa-miR-
342-3p
-5.7 -13.93 -2.33 28.15 0.000228 hsa-miR-
424-5p
-3.36 -9.89 -1.14 32.7 0.002452
hsa-miR-
150-5p
-6.87 -21.08 -2.24 27.23 0.000295 hsa-miR-
150-5p
-3.96 -15.47 -1.02 26.85 0.005019
hsa-miR-
486-5p
-1.29 -2.3 1.39 27.35 0.3626 hsa-miR-
486-5p
-1.14 -1.7 1.31 27.78 0.5245
*miRNAs selected for individual assays are indicated in bold and miR-486-5p was chosen as an endogenous control for data normalization.
doi:10.1371/journal.pone.0155248.t001
Fig 1. Circulating miRNA levels after oral and transdermal administration of T and during the control period. Levels of miR-342 (A) and miR-150
(B) in plasma samples collected from healthy volunteers after administration of oral (gray line) or transdermal (dashed line) T or in the control phase (black
line). Collection time points are indicated on the x-axis. Data were normalized against the corresponding levels of endogenous miR-486-5p. Values are
expressed as means (±SE) of 19 independent samples. (*) indicates statistically significant difference relative to time = 0 h.
doi:10.1371/journal.pone.0155248.g001
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A clear increase in serum free T was apparent from 8 to 24 h after transdermal T administra-
tion. However, ingestion of oral T did not affect serum free T, which followed the same pattern
as during the control period (significant decrease at 8 and 12 h, returning to baseline value at
24 h).
Discussion
In this study, we investigated whether circulating miRNAs could be used to detect testosterone
abuse. Our key finding was that an exogenous source of testosterone triggered an increase in
the level of a specific miRNA relative to a control period during which no treatment was
administered. This observation suggests that this circulating miRNAs may serve as biomarkers
to detect exogenous testosterone intake.
Our screen for potential circulating miRNAs whose levels were altered by testosterone iden-
tified three candidates that might serve as efficient biomarkers of testosterone administration
via different dosage routes. These candidates were confirmed by individual qPCR assays, and
their kinetics were compared with the control results.
Administration of T via either of two routes triggered a significant decrease in the levels of
miR-342 and miR-150. These miRNAs are mainly expressed in white blood cells, and miR-150
is particularly abundant in mature B and T lymphocytes [31, 32]. Levels of both miRNAs
decreased markedly relative to baseline (0 h) 1 day after T administration. WBC count did not
change significantly over the course of the study, eliminating this parameter as an explanatory
variable. One potential explanation for this decrease is the immunosuppressive effect of T,
which might decrease the rate of release of miRNAs fromWBCs [33–35]. However, the kinetics
of natural variations in levels of miR-342 and miR-150 (control) were very similar to the
Fig 2. Circulating miR-122 levels after oral or transdermal T administration and during the control period. Level of plasmamiR-
122 after ingestion of two TU tablets (gray line) and application of two Testopatches (dashed line) or in the control period (black line).
Data were normalized against the corresponding levels of endogenous miR-486-5p Collection time points are indicated on the x-axis.
Values are expressed as means (±SE) of 19 independent samples. (*) indicates statistically significant difference relative to time = 0 h
and the control.
doi:10.1371/journal.pone.0155248.g002
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kinetics of variation during the testosterone phases, especially between 12 and 24 h. The con-
trol and testosterone phases differed primarily in regard to the baseline levels of miR-342 and
miR-150, which were higher during both intervention periods. Therefore, we cannot conclude
that the decrease in both miRNAs was testosterone-dependent, so they cannot serve as bio-
markers for the detection of testosterone. Further investigations should be conducted to char-
acterize the natural variations in the plasma levels of these miRNAs over periods longer than
24 h.
Intake of testosterone, either orally or topically, increased the plasma level of only one
miRNA, which was miR-122. Unlike miR-342 and miR-150, its expression level remained con-
stant throughout the day during the control period, supporting the idea that the peak induction
of plasma miR-122 1 day after T intake was specific to the performance-enhancing drug rather
than the circadian rhythm. miR-122 is expressed primarily in the liver, where it regulates lipid
metabolism [26, 36, 37], and it has already been investigated as a potential biomarker of drug-
induced liver injury [26, 37].
Fig 3. Examples of individual follow-up of miR-122 with personalized threshold. (A and B) Two examples of longitudinal monitoring of plasmamiR-
122 with personalized threshold (indicated by continuous black line) for two volunteers with differentUGT2B17 genotypes (ins/del and ins/ins) after oral
and transdermal intake of T. Thresholds are calculated as the mean of the control phase results + 3 × SD. In these examples, longitudinal monitoring of
plasmamiR-122 levels after oral T administration is more sensitive than of transdermal T administration. Data were normalized against the corresponding
levels of endogenous miR-486-5p.
doi:10.1371/journal.pone.0155248.g003
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The liver is a target organ of testosterone, which influences liver metabolism, suppresses
hepatic protective responses, and promotes hepatocellular carcinoma [38–40]. However, very
little information is available regarding the effect T on hepatic miRNA expression. Delic et al
reported upregulation of six miRNAs, including miR-122, in female mouse liver following 3
weeks of T treatment [41]. In silico analysis identified an androgen response element (ARE) in
the promoter region of miR-122, suggesting that T-induced upregulation of miR-122 is medi-
ated by an interaction between the T-AR complex and its cognate response element. However,
a more detailed understanding of the regulation and function of cell-free miRNAs is required
before we can safely conclude that the increase in plasma miR-122 is the result of direct tran-
scriptional activation by androgen nuclear receptor.
Alternatively, the increase of plasma miR-122 may be the result of T-induced hepatotoxic-
ity, particularly when the drug is taken orally. However, CRP and AST/ALT levels did not vary
significantly, eliminating hepatic inflammation as an explanatory factor. Instead, given that cir-
culating miRNAs may be byproducts of hepatic cells, an increase in cellular activity might
underlie the alterations in release of miRNAs by the liver [21, 42, 43]. Consistent with this idea,
T administered by various routes is metabolized in the liver, increasing hepatocytes activity.
Even though a clear induction of circulating miR-122 was observed 1 day after oral or trans-
dermal T administration, the sensitivity of this method was compromised by the high inter-
individual variability, reflecting the heterogeneity of the volunteers in response to the interven-
tion. Based on the idea of a transcriptomic passport, one appropriate approach would involve
integration of miR-122 level into an individual longitudinal follow-up with a personalized
threshold. To this end, we applied a method that previously yielded successful results in steroid
profiling [6, 7, 30]. In this method, the mean ± 3 × SD of the control values for a given volun-
teer was established as his personalized threshold.
This method has several advantages over previous approaches. First, in contrast to classical
urine biomarkers such as the T/E ratio, commonly used in accredited laboratories, it is inde-
pendent of the UGT2B17 genotype of the subject. Second, expression of plasma miR-122 is
independent of blood-cell count [36]. Third, the detection window is also longer than that
of individual monitoring of typical urinary metabolites, especially in the context of oral T
Fig 4. Serum free T concentrations after oral or transdermal T administration and during the control period.Mean
(±SE) serum free T after oral (gray line) or transdermal (dashed line) T administration or in the control phase (black line).
Values represent the average of 19 independent samples at each time point. (*) indicates statistically significant difference
relative to time = 0 h.
doi:10.1371/journal.pone.0155248.g004
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administration, which is between 2 h and 12 h. However, because a single biomarker is not suf-
ficiently powerful, circulating miR-122 should be combined with several other biomarkers to
increase the sensitivity of testosterone screening.
Recently, a new approach based on individual follow-up of blood steroid hormones by
LC-MS/MS was proposed as a complement to urinary steroid profiling [44]. This method,
which is also independent of UGT2B17 genotype, has the additional advantage that blood
matrix is more stable and less susceptible to confounding factors than urine. However,
although LC-MS/MS effectively detected T after transdermal application, longitudinal moni-
toring after oral TU misuse was less sensitive.
In agreement with this finding, no variation of serum free T was observed after oral TU
ingestion in our study. This surprising observation could be explained by a rapid metabolism
of free T into 5α-dihydrotestosterone, androstenedione and estradiol [45]. Indeed, two studies
reported T retro-conversion to androstenedione following 50 mg oral DHEA or 20 mg andro-
stenedione sublingual ciclodextrin tablet in young males [46, 47]. Finally, food has a particular
importance on the bioavailability of oral TU [48].
On the other side, oral TU ingestion triggered a clear increase in plasma miR-122 with a
larger amplitude than that observed after transdermal administration and a detection window
longer than those of typical urinary biomarkers. The difference between both routes of admin-
istration could be explained by the first-pass effect after oral T administration, associated with
a great increase of hepatocytes activity and miR-122 secretion. In contrast, transdermal systems
slowly deliver T in the body leading to a weaker activity of the liver and a less important secre-
tion of miR-122.
This finding opens the door to using the blood steroid profile in combination with circulating
miRNA signatures to increase the sensitivity of the approach [44]. This integration of multiple
parameters, transcriptomic and metabolomic, in a longitudinal follow-up can improve the dis-
criminatory power of T detection, and thus represents a powerful and efficient tool for targeting
athlete samples for GC-C-IRMS testing. Because both methods require blood samples, the collec-
tion process is simplified, and no additional sample material must to be taken from the athlete.
To address issues of reproducibility and robustness, we chose an endogenous control to coun-
teract the effects of physiological variation in miRNA levels between individuals. To this end, we
identified the least variable miRNAs by screening; miR-486-5p was detected as a circulating miR-
NAs whose abundance was not altered by testosterone via either route of administration. This
miRNA is highly expressed in RBCs [36], is present at high levels in plasma (27.5 Ct), and was
already shown to be an efficient endogenous control in different studies [21, 49]. Therefore, we
chose miR-486-5p as an endogenous control for data normalization of relative expression.
Variations between studies are also related to choice of blood medium, potentially due to
intercellular miRNA trafficking during the coagulation process [19]. In our study, results were
inconsistent between plasma and serum. Expression levels were particularly low in serum, and
our profiling screen was unable to identify any miRNAs that were differentially expressed after
oral ingestion of TU (S4 Table).
The study had several non-negligible limitations. To integrate circulating miRNAs as bio-
markers into the adaptive model of the ABP, intrinsic and extrinsic factors that might affect
measurements of cell-free miRNAs must be fully characterized. In addition, the influence of
confounding factors such as sex, age, high altitude, or physical exercise remains to be deter-
mined. Long-term longitudinal measurement of miR-122 in elite athletes and controls is also
required before this circulating miRNA can be used in an anti-doping context. Monitoring of
plasma miR-122 for a longer period than 24 h would also have been of particular interest.
In summary, our results suggest that transcriptomic biomarkers may be used for detection
of T administered either orally or transdermally. This steroid induced an increase of a specific
Circulating miRNA-122 for Detection of Testosterone Abuse
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miRNA whose origin was related to the liver. Nevertheless, due to high inter-individual vari-
ability, longitudinal and individual measurement was the optimal strategy. When using the
Athlete Biological Passport, a suspicion of doping is based on a combination of several bio-
markers. Therefore, the addition of circulating miRNAs to the adaptive model has the potential
to enhance its discriminatory performance. Our study thus provides the basis for using a com-
bination of steroidomic and transcriptomic biomarkers as a new approach that is complemen-
tary to urine-based methods for detection of testosterone and steroids.
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S1 Fig. Study design. Samples were collected at different time points after application of two
Testopatches (patch phase) at week 2 and the ingestion of two TU tablets (oral phase) at week
5 after a wash-out period of 2 weeks. During the first week of the study, samples were also gath-
ered at the same time points with no treatment (control phase). Circulating miRNAs were
extracted from plasma or serum, reverse transcribed into cDNA and quantitated by RT-qPCR.
Time points selected for the screening are indicated in bold.
(TIF)
S2 Fig. AST/ALT and CRP levels after oral or transdermal T administration or during the
control period. (A and B). Mean (±SE) ALT and AST activity (U/I) at the indicated time
points after testosterone administration. Values represent the average of seven independent
samples (for patch phase) or ten independent samples (for oral phase). (C)Mean (±SE) CRP
(mg/dl) at the indicated time points during each phase. Values represent the average of 19
independent samples at each time point.
(TIF)
S1 Table. Ct values of plasma miRNAs at 0 h and 24 h for each subject in both intervention
periods.
(XLSX)
S2 Table. Total affected plasma miRNAs by oral and transdermal T administration.
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S3 Table. Least variable miRNAs. List of circulating miRNAs whose levels were invariant fol-
lowing oral or transdermal T administration.
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S4 Table. Ct values of serum miRNAs at 0 h and 24 h for each subject in oral period.
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